Oregon’s Psilocybin Centers Face Scrutiny Over Therapy Standards

Undercover Study Reveals Gaps in Oregon Psilocybin Therapy

Researchers conducting an undercover investigation in October 2026 found that several licensed psilocybin centers in Oregon are providing psychedelic services with inconsistent levels of therapeutic support and integration. The study, first reported by The Microdose, involved field researchers posing as clients and documenting their experiences at multiple centers operating under Oregon’s Measure 109 framework. This is the first known systematic attempt to assess real-world practices at state-licensed psilocybin service centers since Oregon’s adult-use program launched in 2023.

The investigation uncovered that while some centers offered structured preparation and integration sessions, others provided psilocybin administration with minimal or no therapeutic guidance. In several cases, facilitators lacked formal clinical backgrounds, and sessions were described as transactional rather than therapeutic. These findings suggest a divergence from the clinical protocols established in federally regulated psychedelic research trials, where psychotherapy is typically considered integral to safety and efficacy.

Oregon’s Legal Framework and Service Center Model

Oregon’s psilocybin program, authorized by Measure 109 and regulated by the Oregon Health Authority (OHA), allows adults over 21 to access psilocybin in supervised settings without a medical diagnosis. The OHA’s rules require that all sessions be facilitated by state-licensed facilitators, but do not mandate that these facilitators be licensed therapists or mental health professionals. Preparation and integration are encouraged but not strictly defined, leaving interpretation up to individual centers. OHA’s official guidelines emphasize safety, informed consent, and harm reduction, but stop short of requiring psychotherapy.

This regulatory flexibility was intended to broaden access and reduce barriers, but it has also resulted in significant variability in service delivery. Unlike clinical trials overseen by the U.S. Food and Drug Administration (FDA), which require standardized protocols and trained therapists, Oregon’s model prioritizes consumer choice and facilitator diversity. However, the undercover study’s findings indicate that this approach may leave some clients without adequate psychological support, especially during challenging experiences.

Implications for Policy, Research, and Clinical Practice

The lack of consistent therapeutic integration in Oregon’s psilocybin centers raises important questions for policymakers, researchers, and clinicians. If therapeutic support is not reliably provided, the risk-benefit profile of legal psilocybin use may differ substantially from that observed in controlled research settings. This discrepancy could influence both public perception and future regulatory decisions at the state and federal levels.

For researchers, the Oregon model offers a unique natural experiment in non-medicalized psychedelic care. However, the absence of standardized therapy complicates efforts to compare outcomes with those from clinical trials. For clinicians, the findings highlight the need for clear referral pathways and post-session support, particularly for clients with underlying mental health conditions. Policymakers may face pressure to tighten regulations or introduce minimum standards for therapeutic involvement, especially if adverse events or negative outcomes are reported.

One non-obvious implication is that insurance providers and liability carriers may become more hesitant to cover facilitators or centers that do not adhere to recognized therapeutic standards, potentially shaping the economics of the emerging industry.

Risks, Unknowns, and the Path Forward

Inconsistent therapeutic integration at Oregon’s psilocybin centers poses risks including inadequate support during acute psychological distress, missed opportunities for long-term benefit, and erosion of public trust in psychedelic care. The true incidence of adverse events in this setting remains unknown, as Oregon’s reporting requirements are less comprehensive than those for FDA-regulated trials.

Key unknowns include the long-term outcomes for clients who receive psilocybin without structured therapy, the effectiveness of harm reduction training for facilitators, and the potential for regulatory intervention if negative outcomes accumulate. The Oregon Health Authority has not yet indicated whether it will revise its guidelines in response to the undercover study, but increased scrutiny from both state and federal agencies is likely.

As other states consider similar models—Colorado’s regulated psilocybin program is set to launch in 2027—the lessons from Oregon will be closely watched. Stakeholders across the field must weigh the trade-offs between access, safety, and clinical rigor as the landscape of psychedelic care continues to evolve.

By Dr. Alex R. Chen, PhD (Clinical Psychology), Psychedelic Research Journal Editor. Reviewed by Dr. Marissa Goldstein, MD (Psychiatry), October 18, 2026. Our research draws on direct regulatory documents, first-party news reporting, and interviews with licensed facilitators.